Chapter 68

Acute Myeloid Leukemia

First published: 04 March 2022

Summary

Acute myeloid leukemia (AML) is the most common type of leukemia in adult human beings, and, even with advances in genetic testing and genetically tailored therapy, the prognosis remains poor. AML involves the clonal expansion of myeloid stem cells, which can either minimally or partially differentiate down a particular myeloid lineage. Genetic defects, such as internal duplications, gene fusions, and point mutations, underlie the pathogenesis of AML. In human medicine, cytomorphologic assessment and phenotyping are essential components of diagnosis; however, genetic analysis has become commonplace and a required part of the diagnostic evaluation of AML. Based on the 2008 updated and 2016 revised WHO criteria, AML is classified into six different categories in human patients: AML with recurrent genetic abnormalities, AML with myelodysplasia-related changes, therapy-associated AML, AML-not otherwise specified, myeloid sarcoma, and myeloid proliferations related to Down's syndrome.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.